Abstract
Objective: The aim of the paper is to investigate the optimum condition for generation of Plasma Activated Media (PAM), where it can deactivate the cancer cells while minimum damage for normal cells.
Background: Over past few years, cold atmospheric Plasma-Activated Media (PAM) have shown its promising application in plasma medicine for treatment of cancer. PAM has a tremendous ability for selective anti-cancer capacity in vitro and in vivo.
Methods: We have analyzed the radicals in air using the optical emission spectroscopy and in culture media using chemical analysis. Further, we have tested the toxicity of PAM using MTT assay.
Results: We observed that more cancer cell death is for the Ar plasma followed by the Ar-N2 plasma, and the least cell death was observed for the Ar-O2 plasma at all treatment times both by direct treatment and through PAM treatment. The concentration of the RNS species is high for Ar-N2 plasma in gas as well as inside the culture media compared to that for pure Ar plasma. However, the difference is significantly less between the Ar plasma treatments and the Ar-N2 plasma treatments, showing that ROS is the main factor contributing to cell death.
Conclusion: Among all three feeding gas plasmas the best system is Ar-O2 plasma for direct treatments towards the cancer cells. In addition, the best system for PAM preparation is Ar-N2 at low time treatments (1 min and 2 min) because it has no effect on normal cells, but kills the cancer cells.
Keywords: Cold atmospheric plasma, plasma activated media, reactive oxygen and nitrogen species, MTT assay, Ar plasma.
Anti-Cancer Agents in Medicinal Chemistry
Title:How Does Plasma Activated Media Treatment Differ From Direct Cold Plasma Treatment?
Volume: 18 Issue: 6
Author(s): Pankaj Attri*, Ji Hoon Park, Anser Ali and Eun Ha Choi*
Affiliation:
- Department of Electrical and Biological Physics, Plasma Bioscience Research Center, Kwangwoon University, Seoul 01897,Korea
- Department of Electrical and Biological Physics, Plasma Bioscience Research Center, Kwangwoon University, Seoul 01897,Korea
Keywords: Cold atmospheric plasma, plasma activated media, reactive oxygen and nitrogen species, MTT assay, Ar plasma.
Abstract: Objective: The aim of the paper is to investigate the optimum condition for generation of Plasma Activated Media (PAM), where it can deactivate the cancer cells while minimum damage for normal cells.
Background: Over past few years, cold atmospheric Plasma-Activated Media (PAM) have shown its promising application in plasma medicine for treatment of cancer. PAM has a tremendous ability for selective anti-cancer capacity in vitro and in vivo.
Methods: We have analyzed the radicals in air using the optical emission spectroscopy and in culture media using chemical analysis. Further, we have tested the toxicity of PAM using MTT assay.
Results: We observed that more cancer cell death is for the Ar plasma followed by the Ar-N2 plasma, and the least cell death was observed for the Ar-O2 plasma at all treatment times both by direct treatment and through PAM treatment. The concentration of the RNS species is high for Ar-N2 plasma in gas as well as inside the culture media compared to that for pure Ar plasma. However, the difference is significantly less between the Ar plasma treatments and the Ar-N2 plasma treatments, showing that ROS is the main factor contributing to cell death.
Conclusion: Among all three feeding gas plasmas the best system is Ar-O2 plasma for direct treatments towards the cancer cells. In addition, the best system for PAM preparation is Ar-N2 at low time treatments (1 min and 2 min) because it has no effect on normal cells, but kills the cancer cells.
Export Options
About this article
Cite this article as:
Attri Pankaj *, Park Hoon Ji , Ali Anser and Choi Ha Eun *, How Does Plasma Activated Media Treatment Differ From Direct Cold Plasma Treatment?, Anti-Cancer Agents in Medicinal Chemistry 2018; 18 (6) . https://dx.doi.org/10.2174/1871520618666180406121734
DOI https://dx.doi.org/10.2174/1871520618666180406121734 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Combination of Conventional Chemotherapy with New Targeted Therapy in Hematologic Malignancies: The Safety and Efficiency of Low- Dose Cytarabine Supports its Combination with New Therapeutic Agents in Early Clinical Trials
Current Cancer Therapy Reviews Liposomes and Lipid Envelope-Type Systems for Systemic siRNA Delivery
Current Pharmaceutical Design Drug Metabolism and Individualized Medicine
Current Drug Metabolism Does Phosphodiesterase 11A (PDE11A) Hold Promise as a Future Therapeutic Target?
Current Pharmaceutical Design Synthesis of Iron Oxide Micro and Nanoparticles from Aluminum Industry Waste and Its Application in the Decolorization of Reactive Blue 235 Dye
Current Pharmaceutical Biotechnology Small Molecule De-Repression of BAX and BAK Oligomerization as a Strategy for Treating Cancer
Letters in Drug Design & Discovery Meet Our Editorial Board Member
Reviews on Recent Clinical Trials Antisense and/or Immunostimulatory Oligonucleotide Therapeutics
Current Cancer Drug Targets Potential Cancer Gene Therapy by Baculoviral Transduction
Current Gene Therapy Chemoinformatics Approaches for Traditional Chinese Medicine Research and Case Application in Anticancer Drug Discovery
Current Drug Discovery Technologies Mesenchymal Stromal Cells Uptake and Release Paclitaxel without Reducing its Anticancer Activity
Anti-Cancer Agents in Medicinal Chemistry Computer Aided Drug Design Approaches for Identification of Novel Autotaxin (ATX) Inhibitors
Current Medicinal Chemistry Mitotic Catastrophe as a Consequence of Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Replicative Oncolytic Herpes Simplex Viruses in Combination Cancer Therapies
Current Gene Therapy Lessons from the Drug Discovery of Lapatinib, a Dual ErbB1/2 Tyrosine Kinase Inhibitor
Current Topics in Medicinal Chemistry The Antiproliferative and Pro-apoptotic Effects of Methoxyamine on Pediatric Medulloblastoma Cell Lines Exposed to Ionizing Radiation and Chemotherapy
Central Nervous System Agents in Medicinal Chemistry Plasticity and Therapeutic Potential of Mesenchymal Stem Cells in the Nervous System
Current Pharmaceutical Design A Screening Method for Potential Anti-pancreatic Cancer Candidate Compounds Based on Hsp90-Cdc37 Interaction Model in vitro
Letters in Drug Design & Discovery Promising Anti-Fibrotic Approaches for Future Treatment of Systemic Sclerosis
Current Rheumatology Reviews Reduced NGF Secretion by HT-29 Human Colon Cancer Cells Treated with a GRPR Antagonist
Protein & Peptide Letters